The firm announced more than 20 million pounds ($27.5 million U.S.) in initial U.K. capital commitments, including a 10 million pound ($13.8 million) commitment from the U.K. medical research charity LifeArc. The U.K. commitments will provide pound-for-pound match funding to every Illumina Accelerator Cambridge or San Francisco Bay Area graduate that secures between 500,000 pounds ($687,550) and 4 million pounds ($5.5 million) in qualified new capital within one year of graduation.

The nine companies are the following:

• BiotaX Labs
• Broken String Biosciences
• Mitra Bio
• MultiplAI Health
• Doloromics
• Flightpath Biosciences
• Oshun Medical
• Parallel Health
• Rubik Therapeutics

Illumina Accelerator is accepting applications for the next funding cycle, due March 1.

Illumina launches genomics incubator in China
Illumina has partnered with investment firm Sequoia Capital China to launch a new collaboration designed to create an incubator for startup companies...

Emedgene, Illumina partner on rare disease analysis
Emedgene and Illumina have partnered to interpret genomic data for rare diseases.

Firms partner with Microsoft to advance DNA data storage
Twist Bioscience, Illumina, and Western Digital have formed an alliance with Microsoft to advance the field of DNA data storage.

Arc Bio offers early access to Galileo One test
Arc Bio has announced the launch of an early access program for its Galileo One next-generation sequencing test, previewing the product this week at the...

Illumina's Q2 revenue drops 25%
Illumina's revenue dropped 25% due to the impact of the COVID-19 pandemic on the company's business in the second quarter. The company's net income also...